REGN vs VRE · P/E 14, rev $14.34B vs rev $271.1M
Regeneron Pharmaceuticals Inc (REGN) versus Veris Residential Inc (VRE) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Veris Residential Inc (VRE) is a reit - residential company listed on US.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported VRE revenue for 2024-12-31 was $271.1M. Net income was -$26.7M. Revenue was up 4.1% from 2023-12-31 to 2024-12-31. VRE currently screens at market cap $1.61B.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. VRE currently screens at market cap $1.61B.
Not investment advice. Open the REGN and VRE stock pages for the full models.
Not investment advice.